WaveSense

Press Kits:

Questions?

Salem, New Hampshire, August 22, 2007 – AgaMatrix, Inc., recently introduced its second blood glucose meter, the WaveSense Jazz™ at the Annual Meeting of the American Association of Diabetes Educators (AADE) in August in St. Louis.  The WaveSense Jazz blood glucose meter has market-leading features, including no coding and one of the world’s largest backlit digits for easy reading. The WaveSense Jazz also has a number of other advanced features designed to help people with diabetes gain tighter control over their blood glucose levels.

The WaveSense Jazz is one of the first meters on the market to provide a score for a user’s glycemic variability. Glycemic variability is a tool often used to show how often blood sugar changes over a period of time and how intense these fluctuations are. Glycemic variability may also allow for an end-user and their health care professional to better analyze the effect of high and low readings over specific days, weeks or months.

"I was really excited at AADE to see the new Jazz meter! That we now have a way to much better understand glycemic variability through blood glucose monitoring strikes me as a real step forward. Jazz is the first meter that I know of to offer a measure of glycemic variation on the screen itself. Although conceptually, glycemic variation is far from a standard concept today, it’s a terrific start to be able to put this valuable data into the hands of patients that choose it and to explain why it matters so they can reduce the highs and lows that they experience every day. To boot, glycemic variation is shown on the Jazz meter in an easy-to-understand way that will enable many patients to engage in their care and to more easily intensify and improve their diabetes self- management  - themselves! This will really help patients who are eager to dig into data more easily develop an understanding of their meaning and improve their self- management." stated Kelly Close of Close Concerns Inc. in the August issue of Diabetes Close Up.

Other WaveSense Jazz features that were designed to help users gain tighter control include:

• Automatic mealtime tagging: Smart before and after meal tagging (breakfast, lunch, dinner, and nighttime) allows the patient to change the tag based on their personal schedule to provide more useful information when analyzing glucose readings.

• Positive feedback feature: Alerts the user if their blood glucose result is within their pre- and post- meal target range to encourage tighter control. The ranges can be easily changed by the user or their health care professional.

• Compliance tracker feature: Displays the average number of tests/day.

• Very large memory: 1,865 memories for an average of 5 times/day for one year.

• Wireless version: A special wireless version has Bluetooth connectivity for automatic and secure transfer of glucose results.

“Tighter blood sugar control for a person with diabetes will always decrease the chance of having secondary complications from diabetes,” said Dr. Bruce Bode, one of the world’s leading experts on intensive diabetes management.  “The WaveSense Jazz has all the best advanced features needed to help a patient gain and maintain tighter control in the best interest of their health.”

The Jazz, like the Company’s first meter, the KeyNote, is also powered by WaveSense™. WaveSense technology is a suite of patented technologies that enable high accuracy glucose monitoring products.  WaveSense employs Dynamic Electrochemistry™ to extract a spectrum of information inaccessible to traditional static electrochemistry methods. WaveSense technology aids in the detection of a wide range of variables that can distort a glucose reading, these variables can be corrected through advanced signal processing algorithms in the meter, thus leading to more accurate readings.

“Accuracy should be important to any person that has a need to test their blood glucose. Patients often give up on testing because the readings seem to make no sense.  WaveSense products are able to bring accuracy to a consistent repeatable level,” states Dave Joffe, Editor-in-Chief of Diabetes in Control and a leading pharmacist and diabetes educator. “It is about time a company took advantage of the technology advancements available and designed an affordable, accurate system with the patient in mind."

The WaveSense Jazz is pending 510(k) FDA clearance and it is expected to be available in the fall of 2007.

About AgaMatrix

AgaMatrix is a technology company headquartered in Salem, New Hampshire that develops and manufactures next generation blood glucose monitoring (BGM) products for the diabetes market. The Company's proprietary WaveSense biosensor technologies (www.wavesense.info) enable significantly higher accuracy glucose sensing. Current products include a line of meter and strip systems and a blood glucose data management software system.
 

Download PDF